Lonza Shares Rise on Sales, Earnings Beat
By David Sachs
Lonza shares jumped Friday after the company posted consensus-beating sales and earnings.
At 0858 GMT, shares in the Swiss life-sciences company were up 13% at CHF419.30 after rising as high as CHF420.90.
Lonza's full-year sales of 6.72 billion Swiss francs ($7.75 billion) were 3% above the company-compiled consensus, while core earnings before interest, taxes, depreciation and amortization were 5% ahead at CHF2.00 billion, Jefferies analysts said in a note.
Jefferies said the stronger second half of last year should offset negative currency affects and could trigger small consensus updates, which is better than the downside risk feared by the analysts.
Lonza also nominated Jean-Marc Huet to replace Albert Baehny as chairman, but the move shouldn't disrupt the group's crucial search for a new chief executive, Jefferies said.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
January 26, 2024 04:23 ET (09:23 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
After Earnings and a 56% Rally In 2024, Is Arm Stock a Buy, a Sell, or Fairly Valued?
-
How Morningstar Rates Stocks
-
After Earnings, Is Disney Stock a Buy, a Sell, or Fairly Valued?
-
Home Depot Earnings: Macro Factors Pinch Demand, but Long-Term Outlook Intact
-
Tariffs On Chinese EVs Offer US Automakers a Chance to Capture Demand
-
The Best REITs to Buy
-
3 Hot Stocks to Buy That Still Look Undervalued
-
After Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?